Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 9Hyperandrogenism 4Neoplasms 3Skin Diseases 1Sarcoma 1Rare Diseases 1Obesity 1Metabolic Syndrome 1Lymphoma 1Leukemia, Myeloid, Acute 1Inflammation 1Hematologic Neoplasms 1Heart Failure 1Glioblastoma 1Endocrine System Diseases 1Critical Illness 1Cardiovascular Diseases 1Cardiotoxicity 1Breast Neoplasms 1Advanced Malignant Neoplasm 1Acute Kidney Injury 1Acanthosis Nigricans 1

Interventions

binimetinib 2Sodium Chloride 2Aminolevulinic Acid 2palbociclib 1methyl 5-aminolevulinate 1ipatasertib 1exemestane 1encorafenib 1baricitinib 1atezolizumab 1Vemurafenib 1VP-102 1Trabectedin 1Spironolactone 1Radiotherapy 1Radiation 1Photochemotherapy 1Paclitaxel 1Low-Level Light Therapy 1Leuprolide 1Injections, Intradermal 1Gonadotropin-Releasing Hormone 1Fluorouracil 1Floderm topical cream 1Everolimus 1Equipment and Supplies 1Docetaxel 1Dacarbazine 1Cetuximab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Skin Diseases × Spironolactone × Clear all
NCT00004311 2005-06-24

Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome

Office of Rare Diseases (ORD)

Phase 2 Completed

Acanthosis Nigricans, Endocrine System Diseases, Polycystic Ovary Syndrome, Skin Diseases, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡